Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease
A Phase IIb Multi-Center, Open-label, Follow-up Study to Assess Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Who Participated in Study SL0007
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium
-
Leuven, Belgium
-
-
-
-
-
Porto Alegre, Brazil
-
Sao Paulo, Brazil
-
-
GO
-
Goiania, GO, Brazil
-
-
-
-
-
Shatin, Hong Kong
-
-
-
-
-
Debrecen, Hungary
-
Zalaegerszeg, Hungary
-
-
-
-
-
Bangalore, India
-
Hyderabad, India
-
Manipal, India
-
Nagpur, India
-
-
Tamilnadu
-
Madurai, Tamilnadu, India
-
-
-
-
-
Kaunas, Lithuania
-
Klaipeda, Lithuania
-
Vilnius, Lithuania
-
-
-
-
-
Elblag, Poland
-
Konskie, Poland
-
Lublin, Poland
-
Poznan, Poland
-
Torun, Poland
-
-
-
-
-
Barcelona, Spain
-
Santander, Spain
-
-
-
-
-
Donetsk, Ukraine
-
Ivano-Frankivsk, Ukraine
-
Kiev, Ukraine
-
Lviv, Ukraine
-
-
-
-
-
Birmingham, United Kingdom
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
Arizona
-
Tucson, Arizona, United States
-
-
California
-
La Jolla, California, United States
-
Los Angeles, California, United States
-
San Leandro, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Connecticut
-
Farmington, Connecticut, United States
-
-
Florida
-
Tampa, Florida, United States
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
Charlotte, North Carolina, United States
-
Durham, North Carolina, United States
-
Wilmington, North Carolina, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Virginia
-
Arlington, Virginia, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- SL0007 patients who completed through week 12 of the study or who early terminated at week 8 or later due to treatment failure
- Patients must have maintained eligibility requirements throughout their participation in SL0007
- Written informed consent signed prior to initiation of any study-specific assessments at visit 1
Exclusion Criteria:
- Patients may not receive any live vaccination within 2 weeks prior to visit 1 or during the course of the study
- Active severe SLE disease activity which involves the CNS system (defined by BILAG neurologic A level activity) including transverse myelitis, psychosis and seizures
- Active severe SLE disease activity which involves the Renal system (defined by BILAG renal level A activity or Grade III or higher WHO nephritis) or serum creatinine >2.5mg/dL or clinically significant serum creatinine increase within the prior 4 weeks or proteinuria >3.5gm/day
- Patients with a history of anti-phospholipid antibody syndrome AND Use of oral anticoagulants or anti-platelet treatment
- Patients with a history of chronic infection, recent significant infection, or any current sign of symptom that may indicate an infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: EMAB
1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.
|
Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Continue to assess safety of epratuzumab by assessing adverse events (including infusion reactions), vital signs and clinical safety laboratory assessments (Timeframe: All visits)
Time Frame: 12 Week treatment cycles
|
12 Week treatment cycles
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The combined response index analysis evaluating BILAG, SLEDAI, and a physician's global assessment and treatment failure status
Time Frame: Every 4 weeks through week 48, then every 12 weeks through completion
|
Every 4 weeks through week 48, then every 12 weeks through completion
|
|
The combined response index including an additional criteria involving the SF-36 response
Time Frame: Every 12 weeks
|
Every 12 weeks
|
|
BILAG score assessment
Time Frame: Every 4 weeks through week 48, then every 12 weeks through completion
|
Every 4 weeks through week 48, then every 12 weeks through completion
|
|
SLEDAI scores assessment
Time Frame: Every 4 weeks through week 48, then every 12 weeks through completion
|
Every 4 weeks through week 48, then every 12 weeks through completion
|
|
Patient and physician VAS
Time Frame: Every 4 weeks through week 48, then every 12 weeks through completion
|
Every 4 weeks through week 48, then every 12 weeks through completion
|
|
Percentage of patients achieving SF-36 stabilization or improvement as compared to baseline
Time Frame: Every 12 weeks
|
Every 12 weeks
|
|
SF-36 PCS, MCS
Time Frame: Every 12 weeks
|
Every 12 weeks
|
|
EQ-5D results
Time Frame: Every 12 weeks
|
Every 12 weeks
|
|
Proportion of patients meeting treatment failure
Time Frame: Every 12 weeks
|
Every 12 weeks
|
|
Total daily steroid dose
Time Frame: Every 4 weeks for the first 48 weeks and then every 12 weeks
|
Every 4 weeks for the first 48 weeks and then every 12 weeks
|
|
Time to flare for patients who entered the study without flare as defined by the BILAG
Time Frame: over the entire course of the trial
|
over the entire course of the trial
|
|
SLEDAI responder
Time Frame: Every 4 weeks for the first 48 weeks and then every 12 weeks
|
Every 4 weeks for the first 48 weeks and then every 12 weeks
|
|
Time to sustained response for patients entering SL0008 with flare as defined by the BILAG.
Time Frame: over the entire course of the trial
|
over the entire course of the trial
|
|
Immunogenicity as measured by human anti-human antibodies
Time Frame: at each dosing visit and 4 weeks post first dose of each treatment cycle
|
at each dosing visit and 4 weeks post first dose of each treatment cycle
|
|
Assessment of changes in baseline in levels of circulating B and T cells
Time Frame: The first dosing visit of each treatment cycle and at 4 weeks post first dose of each treatment cycle
|
The first dosing visit of each treatment cycle and at 4 weeks post first dose of each treatment cycle
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.
- Wallace DJ, Hobbs K, Clowse ME, Petri M, Strand V, Pike M, Merrill JT, Leszczynski P, Neuwelt CM, Jeka S, Houssiau F, Keiserman M, Ordi-Ros J, Bongardt S, Kilgallen B, Galateanu C, Kalunian K, Furie R, Gordon C. Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. Arthritis Care Res (Hoboken). 2016 Apr;68(4):534-43. doi: 10.1002/acr.22694.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SL0008
- EudraCT Number: 2007-002589-37
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.